New cell therapy takes aim at Hard-to-Treat cancers
NCT ID NCT07394205
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests an experimental treatment called CBG131 for adults with advanced stomach or pancreatic cancer that has a specific marker (CLDN18.2). The therapy uses a patient's own immune cells, modified in a lab to target and attack cancer cells. The main goals are to check safety, find the best dose, and see if it can shrink tumors. About 18 participants will receive a single infusion after a short course of chemotherapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED GASTRIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, 325000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Pan-RAS inhibitor outsmart pancreatic cancer?
- Experimental drug combo targets Hard-to-Treat GI cancers
- New Antibody-Drug combo takes on Hard-to-Treat pancreatic cancer
- New drug combo aims to shrink Hard-to-Treat pancreatic and ovarian tumors
- Drug cocktail aims to stall pancreatic cancer in patients who have run out of options
- New drug cocktail aims to tackle Hard-to-Treat stomach cancer